The Neurosurgery Reimbursement Landscape
The dollars are enormous. The commercial contract decides who keeps them.
In neurosurgery, a handful of high-acuity cases carry the book — and the gap between commercial and Medicare rates is so wide that the commercial contract, not the fee schedule, decides the economics.
An instrumented spine fusion, a craniotomy, or a functional case can be reimbursed at a large multiple of Medicare under a strong commercial contract — and near breakeven under a weak one. Because these procedures carry high-cost implants, biologics, and facility resources, how implant and facility carve-outs are written, whether cost-outliers and multiple-procedure reductions are protected, and how intraoperative neuromonitoring and assistant-surgeon services are paid can swing the margin on a single case by six figures.
Neurosurgery is also overwhelmingly hospital- and facility-based, which concentrates out-of-network exposure and puts the No Surprises Act and its independent dispute resolution (IDR) process squarely in play. Layer on prior-authorization and medical-necessity denials on spine surgery, and rapid consolidation into hospital co-management and PE-backed platforms, and the same case can be worth dramatically different amounts depending on how it is contracted, defended, and collected — which is precisely where Fulcrum works.
Illustrative composition. Replace with your confirmed figures before launch; reflects current CMS/MedPAC methodology and public payer data, 2024–2026.